

**Emmanuel Caeymaex****Executive Vice President Patient Evidence****Joined UCB in March 1994****Appointed in 2015****Nationality: Belgian****Introduction & Professional experience**

Emmanuel heads UCB's Patient Evidence organization, bringing together global functions and stakeholders to shape the strategy and generate the robust evidence needed to demonstrate the value of UCB's medicines. His remit includes Development, Medical Affairs, Strategic Marketing, Market Access and HTA, Real-World Evidence and Patient Safety, as well as engagement with external partners such as regulatory authorities, patient organisations and public bodies. He leads the translation of scientific innovation into meaningful outcomes, strengthening UCB's portfolio strategy and advancing medicines across severe diseases — including rare epileptic syndromes, rare neuromuscular disorders, autoimmune dermatology and rheumatology, and musculoskeletal conditions.

As a leader at UCB, Emmanuel is deeply committed to enhancing patient experience and championing health equity, while fostering an inclusive environment where colleagues can excel and grow. Drawing on his extensive experience in global commercialization and product launches, he brings a pragmatic, end-to-end perspective to evidence generation, helping ensure that development choices are grounded in real-world patient and healthcare system needs and support UCB's decade of sustainable growth.

Emmanuel has been instrumental in advancing UCB's transformation into a global biopharma company focused on patients with severe diseases. Most recently, he served as UCB's Chief Commercial Officer, where he played a critical role in the successful global launch and lifecycle development of several of UCB's key medicines. Prior to this, he led UCB's Immunology Solutions unit, directly ran UCB's US operations, and previously headed UCB's main cross-functional asset team.

Emmanuel formerly served as President of UCB Japan Co., Ltd., and earlier contributed to building UCB's leadership position in epilepsy through senior global marketing and business unit leadership roles. At the beginning of his career, Emmanuel established and ran UCB's operations in several Asia-Pacific markets, for which he was awarded the Laureate of the Prince Albert Fund.

**Education**

Emmanuel received a Business Engineer MSc degree from the University of Louvain (UCL), Belgium, a Master's in International Management from the Community of European Management Schools (CEMS) and continued his executive leadership development journey at INSEAD.



**Main external appointments**

President, Prince Albert Fund, Brussels.

Chairman, Inteliphage SRL, Louvain-la-Neuve, Belgium